Market capitalization | $267.43m |
Enterprise Value | $-215.75m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.79 |
EV/Sales (TTM) EV/Sales | -6.16 |
P/S ratio (TTM) P/S ratio | 7.64 |
P/B ratio (TTM) P/B ratio | 0.42 |
Revenue growth (TTM) Revenue growth | -47.37% |
Revenue (TTM) Revenue | $35.00m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a ITeos Therapeutics Inc forecast:
5 Analysts have issued a ITeos Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 35 35 |
47%
47%
|
|
Gross Profit | 34 34 |
48%
48%
|
|
EBITDA | -149 -149 |
61%
61%
|
EBIT (Operating Income) EBIT | -150 -150 |
61%
61%
|
Net Profit | -121 -121 |
97%
97%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Michel Detheux |
Employees | 157 |
Founded | 2012 |
Website | www.iteostherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.